Resilience is a pioneering remote patient monitoring (RPM) platform transforming cancer care. Founded in February 2021 by French entrepreneurs Céline Lazorthes and Jonathan Benhamou, both successful serial entrepreneurs—Céline, known for founding Leetchi and its spin-off Mangopay, and Jonathan, co-founder of MyPeopleDoc—Resilience integrates a beautifully designed mobile app with an innovative RPM platform, empowering patients to manage cancer treatment effects while improving quality of life and clinical outcomes.

With features like machine-learning-enhanced clinical guidelines, symptom tracking, and digital support programs (e.g., yoga, meditation, and CBT), Resilience has rapidly scaled, serving over 10,000 patients across 90+ medical centers.

In a groundbreaking achievement, Resilience became the first remote monitoring medical device in oncology to receive reimbursement from the French national social security system in October 2023. This milestone, achieved after rigorous validation by the regulatory agency HAS, underscores the clinical and organizational value of Resilience's solution and paves the way for wider adoption and accessibility of their innovative platform.

At Red River West, we believe Resilience has the potential to become a European leader in RPM before targeting the substantial US market, aligning perfectly with our thesis of supporting European leaders poised for global expansion.

Furthermore, Resilience is expanding its reach beyond oncology, opening new verticals in RPM such as Inflammatory Bowel Disease (IBD), demonstrating the versatility and potential of their platform to address a wide range of chronic conditions.